These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37913904)

  • 1. The Influence of Precursor Depletion and dose Regimens on Resistance to Erythropoiesis-Stimulating Agents: Insights from Simulations with Instantaneous Dose-Adaptation Algorithm.
    Xu P; Wong RSM; Yan X
    J Pharm Sci; 2024 Jan; 113(1):246-256. PubMed ID: 37913904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease.
    Kuwahara M; Mandai S; Kasagi Y; Kusaka K; Tanaka T; Shikuma S; Akita W
    Clin Exp Nephrol; 2015 Aug; 19(4):598-605. PubMed ID: 25183365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Patients with Non-Dialysis-Dependent Chronic Kidney Disease (RADIANCE-CKD Study).
    Mase K; Yamagata K; Yamamoto H; Tsuruya K; Hase H; Nishi S; Nangaku M; Wada T; Hayashi T; Uemura Y; Hirakata H
    Am J Nephrol; 2023; 54(11-12):471-478. PubMed ID: 37793365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease.
    Minutolo R; Garofalo C; Chiodini P; Aucella F; Del Vecchio L; Locatelli F; Scaglione F; De Nicola L
    Nephrol Dial Transplant; 2021 Jan; 36(2):267-274. PubMed ID: 32829405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
    Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
    Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
    Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
    PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
    Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
    BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective.
    Gauthier-Loiselle M; Michalopoulos SN; Cloutier M; Serra E; Bungay R; Szabo E; Guérin A
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1703-1713. PubMed ID: 34818094
    [No Abstract]   [Full Text] [Related]  

  • 11. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
    Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
    BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR
    Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.
    Miura T; Sato T; Yano T; Takaguri A; Miki T; Tohse N; Nishizawa K
    Cardiovasc Drugs Ther; 2023 Dec; 37(6):1175-1192. PubMed ID: 35150385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
    Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
    Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.
    Hörbrand F; Bramlage P; Fischaleck J; Hasford J; Brunkhorst R
    Eur J Clin Pharmacol; 2013 Apr; 69(4):929-36. PubMed ID: 23052412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Treatment Approaches for the Anemia of CKD.
    Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
    Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron Metabolism in Chronic Kidney Disease Patients.
    Honda H; Hosaka N; Ganz T; Shibata T
    Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.
    Chiloff DM; de Almeida DC; Dalboni MA; Canziani ME; George SK; Morsi AM; El-Akabawy N; Porada CD; Durao MS; Zarjou A; Almeida-Porada G; Goes MA
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F861-F869. PubMed ID: 32003597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.
    Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T
    Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.